CAJ | 학술논문

目的观察替比夫定治疗慢性乙型重型肝炎的临床疗效.方法随机将60例慢性乙型重型肝炎患者分为2组,对照组30例采用常规综合治疗,治疗组30例常规综合治疗的基础上加用替比夫定600mg,每日一次口服.观察两组在治疗前及后在2周、4周、12周的HBVDNA,治疗前后肝功能,PTA,评估临床疗效.结果治疗组HBVDNA阴转率2,4,12周分别为33.0%,80.0%,83.3%,对照组分别为0%,3.3%,10.0%两组比较差异有统计学意义(P均＜0.01).治疗4周后,与对照组比较在TBil降低(P＜0.01)、PTA升高(P＜0.01)方面有统计学意义,治疗组总有效率67.7%,对照组40.0%(P＜0.05).结论替比夫定有较强的抗HBVDNA活性,且起效快,能显著改善肝功能,适合重型肝炎患者使用.
목적 관찰체비부정치료만성을형중형간염적림상료효.방법 수궤장60례만성을형중형간염환자분위2조,대조조30례채용상규종합치료,치료조30례상규종합치료적기출상가용체비부정600mg,매일일차구복.관찰량조재치료전급후재2주、4주、12주적HBVDNA,치료전후간공능,PTA,평고림상료효.결과 치료조HBVDNA음전솔2,4,12주분별위33.0%,80.0%,83.3%,대조조분별위0%,3.3%,10.0%량조비교차이유통계학의의(P균＜0.01).치료4주후,여대조조비교재TBil강저(P＜0.01)、PTA승고(P＜0.01)방면유통계학의의,치료조총유효솔67.7%,대조조40.0%(P＜0.05).결론 체비부정유교강적항HBVDNA활성,차기효쾌,능현저개선간공능,괄합중형간염환자사용.
Objective To investigate the clinical efficacy of Telbivudine in the treatment of chronic severe hepatitis B.Methods 60 patients with chronic severe hepatitis B were randomly divided into 2 groups. The control group(n=30) was given conventional therapy, while the treatment group treated with telbivudine,600mg daily,on the basis of routine. Before and after treatment for 2, 4, 12 weeks, the level of HBV DNA of the two groups were detected, and hepatic function and PTA measured on the forth week. The efficacy of treatment at the forth week was evaluated.Results HDV DNA negative conversion rate of 33%(after 2 weeks), 80%(after 4 weeks) and 83.3% (after 12 weeks) in treatment, that was significantly higher than those in control group (0 after 2 weeks, 3.3% after 4 weeks, and 10% after 12 weeks)(P <0.01). After treatment for 4 weeks, the improvement of TBil and PTA in treatment group were much better than those in the control group (P<0.01),The total effective rates of treatment group and control group were 67.7% and 40% (P＜0.05).Conclusion Telbivudine had an strong anti-HBV activity, and a rapid effect. It will significantly improve the hepatic function for patients with severe hepatitis B.